461 related articles for article (PubMed ID: 23921128)
1. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells.
Chen CL; Tsukamoto H; Liu JC; Kashiwabara C; Feldman D; Sher L; Dooley S; French SW; Mishra L; Petrovic L; Jeong JH; Machida K
J Clin Invest; 2013 Jul; 123(7):2832-49. PubMed ID: 23921128
[TBL] [Abstract][Full Text] [Related]
2. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus.
Machida K; Chen CL; Liu JC; Kashiwabara C; Feldman D; French SW; Sher L; Hyeongnam JJ; Tsukamoto H
J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2(Suppl 2):19-22. PubMed ID: 22320911
[TBL] [Abstract][Full Text] [Related]
4. TLR4 Signaling via NANOG Cooperates With STAT3 to Activate Twist1 and Promote Formation of Tumor-Initiating Stem-Like Cells in Livers of Mice.
Uthaya Kumar DB; Chen CL; Liu JC; Feldman DE; Sher LS; French S; DiNorcia J; French SW; Naini BV; Junrungsee S; Agopian VG; Zarrinpar A; Machida K
Gastroenterology; 2016 Mar; 150(3):707-19. PubMed ID: 26582088
[TBL] [Abstract][Full Text] [Related]
5. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
6. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
8. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer.
Chen WC; Chang YS; Hsu HP; Yen MC; Huang HL; Cho CY; Wang CY; Weng TY; Lai PT; Chen CS; Lin YJ; Lai MD
Oncotarget; 2015 Dec; 6(40):42923-37. PubMed ID: 26556861
[TBL] [Abstract][Full Text] [Related]
9. TLR4-dependent tumor-initiating stem cell-like cells (TICs) in alcohol-associated hepatocellular carcinogenesis.
Machida K; Feldman DE; Tsukamoto H
Adv Exp Med Biol; 2015; 815():131-44. PubMed ID: 25427905
[TBL] [Abstract][Full Text] [Related]
10. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.
Lin L; Amin R; Gallicano GI; Glasgow E; Jogunoori W; Jessup JM; Zasloff M; Marshall JL; Shetty K; Johnson L; Mishra L; He AR
Oncogene; 2009 Feb; 28(7):961-72. PubMed ID: 19137011
[TBL] [Abstract][Full Text] [Related]
11. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
12. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
13. NANOG Metabolically Reprograms Tumor-Initiating Stem-like Cells through Tumorigenic Changes in Oxidative Phosphorylation and Fatty Acid Metabolism.
Chen CL; Uthaya Kumar DB; Punj V; Xu J; Sher L; Tahara SM; Hess S; Machida K
Cell Metab; 2016 Jan; 23(1):206-19. PubMed ID: 26724859
[TBL] [Abstract][Full Text] [Related]
14. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.
Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879
[TBL] [Abstract][Full Text] [Related]
15. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
[TBL] [Abstract][Full Text] [Related]
16. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
17. Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
Chang HL; Chen HA; Bamodu OA; Lee KF; Tzeng YM; Lee WH; Tsai JT
Toxicol In Vitro; 2018 Sep; 51():74-82. PubMed ID: 29698666
[TBL] [Abstract][Full Text] [Related]
18. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
19. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
20. Alcohol, TLR4-TGF-β antagonism, and liver cancer.
Tsukamoto H; Mishra L; Machida K
Hepatol Int; 2014 Sep; 8 Suppl 2(Suppl 2):408-12. PubMed ID: 26201318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
